We cannot expand the study population for further research, and we suggest dynamic monitor of CD14+HLA-DRlo/neg MDSCs in COVID-19 patients could help to evaluate its detailed clinical values and roles in development of COVID-19 in current outbreak areas. This evidence concerns the gene CD14 and COVID-19.